Cocrystal Pharma Inc COCP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if COCP is a good fit for your portfolio.
News
-
Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor
-
New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows
-
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
-
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
Trading Information
- Previous Close Price
- $2.22
- Day Range
- $2.19–2.22
- 52-Week Range
- $1.33–3.29
- Bid/Ask
- $2.20 / $2.92
- Market Cap
- $22.38 Mil
- Volume/Avg
- 9,435 / 34,149
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 12
- Website
- https://www.cocrystalpharma.com
Valuation
|
Metric
|
COCP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.99 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
COCP
Financial Strength
|
Metric
|
COCP
|
|---|---|
Quick Ratio | 9.60 |
Current Ratio | 10.30 |
Interest Coverage | — |
Quick Ratio
COCP
Profitability
|
Metric
|
COCP
|
|---|---|
Return on Assets (Normalized) | −56.78% |
Return on Equity (Normalized) | −62.69% |
Return on Invested Capital (Normalized) | −63.78% |
Return on Assets
COCP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Jnlrtznpx | Crssc | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Mfttvytz | Hjmwwb | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mzbzbgzz | Vrclcr | $118.7 Bil | |||
| Moderna Inc
MRNA
| Jgjkczt | Hynrg | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cppnmtdr | Ykvvc | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Pmljplws | Mvv | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Cgkxlyk | Bpq | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lsvxhqphk | Tzgxwvx | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Szyyqdbp | Ymsft | $15.0 Bil | |||
| Incyte Corp
INCY
| Kgfzwwnh | Tclvq | $13.5 Bil |